Recurrence of clostridium difficile infection in patients with inflammatory bowel disease: The RECIDIVISM study

American Journal of Gastroenterology

Volumn 111, Issue 8, 2016, Pages 1141-1146

  Razik, Roshan ^a,b,c   Rumman, Amir ^a   Bahreini, Zoya ^a   Mcgeer, Allison ^a   Nguyen, Geoffrey C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; STEROID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; GLUCOCORTICOID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEROID THERAPY; TREATMENT OUTCOME; ULCERATIVE COLITIS; AGED; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; CROHN DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HOSPITALIZATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MESALAMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84970004349     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.187     Document Type: Article

References (23)

1. Bartlett JG. Clinical practice. Antibiotic-Associated diarrhea. N Engl J Med 2002; 346: 334-9.
2. McDonald LC, Owings M, Jernigan DB. C lostridium diffi cile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-15.
3. Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium diffi cile colitis in hospitalized patients in the United States. Arch Surg 2007; 142: 624-31.
4. Hashash JG, Binion DG. Managing Clostridium diffi cile in Inflammatory bowel disease (IBD). Curr Gastroenterol Rep 2014; 16: 393.
5. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium diffi cile infection among hospitalized Inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
6. Seril DN, Ashburn JH, Lian L, et al. Risk factors and management of refractory or recurrent Clostridium diffi cile infection in ileal pouch patients. Inflamm Bowel Dis 2014; 20: 2226-33.
7. Garey KW, Sethi S, Yadav Y, et al. Meta-Analysis to assess risk factors for recurrent Clostridium diffi cile infection. J Hosp Infect 2008; 70: 298-304
8. Johnson S. Recurrent Clostridium diffi cile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10.
9. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium diffi cile in adults: a systematic review. JAMA 2015; 313: 398-408.
10. McCoy RM, Klick A, Hill S, et al. Lumnial toxin-binding agents for Clostridium diffi cile infection. J Pharm Pract 2016 (e-pub ahead of print).
11. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium diffi cile infection: a review. Dig Dis Sci 2011; 56: 19-26.
12. Issa I, Moucari R. Probiotics for antibiotic-Associated diarrhea: do we have a verdict? World J Gastroenterol 2014; 20: 17788-95.
13. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium diffi cile infection. N Engl J Med 2011; 364: 422-31.
14. Masclee GM, Penders J, Jonkers DM, et al. Is C lostridium diffi cile associated with relapse of Inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis 2013; 19: 2125-31.
15. Olsen MA, Yan Y, Reske KA, et al. Recurrent C lostridium diffi cile infection is associated with increased mortality. Clin Microbiol Infect 2014; 21: 164-70.
16. Deshpande A, Pasupleti V, Thota P, et al. Risk factors for recurrent Clostridium diffi cile infection: a systematic review and meta-Analysis. Infect Control Hosp Epidemiol 2015; 00: 1-9.
17. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium diffi cile infection. Gastroenterology 2009; 136: 1206-14.
18. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium diffi cile diarrhea. Lancet 2001; 357: 189-93.
19. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to Clostridium diffi cile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-9.
20. D?Agostino RB, Collins SH, Pencina KM, et al. Risk estimation for recurrent Clostridium diffi cile infection based on clinical factors. Clin Infect Dis 2014; 58: 1386-93.
21. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn?s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9.
22. Li Y, Qian J, Queener E, et al. Risk factors and outcome of PCR-detected Clostridium diffi cile infection in ileal pouch patients. Inflamm Bowel Dis 2013; 19: 397-403.
23. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med 2014; 34: 771-85.